Botox shows favorable long-term outcomes for OAB and urinary incontinence

“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.

In this video, David A. Ginsberg, MD, discusses the background and findings of the study, “Long-term, repeat treatments with onabotulinumtoxinA (Botox) are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.